BioArctic and partner Eisai presented new real-world data at the 2026 AD/PD conference showing that most early Alzheimer's patients in the US continue lecanemab treatment beyond 18 months, with 67.3% still on therapy at 24 months. This persistence aligns with clinical trial results indicating sustained benefits from long-term use. BioArctic also highlighted research on lecanemab's targeted action in the brain and ongoing trials for Parkinson's disease using related antibodies. These findings support lecanemab's potential as a long-term treatment option and underscore BioArctic's active role in neurodegenerative disease research and commercialization efforts.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
XRP surged about 4% to $1.11 following a broader crypto market rebound triggered by softer U.S. inflation data. Technical signals suggest a bullish inverse head and shoulders pattern, with potential for a 20% price increase if XRP breaks the $1.12–$1...
Revolut has received preliminary approval from Dubai's Virtual Assets Regulatory Authority to offer cryptocurrency services in the UAE, including broker-dealer, asset management, and exchange functions. This approval allows UAE customers to trade and...
Rotork PLC has accepted a £4.1 billion takeover bid from Swiss engineering group ABB, offering shareholders 506p per share, a 73% premium over the previous closing price. The acquisition will enhance ABB's industrial automation business by adding Rot...
Alexandria Real Estate Equities (ARE) is struggling with oversupply and vacancy rates exceeding 30% in key life science markets like Boston, San Francisco, and San Diego. This has caused an 80% decline in its stock price from its peak. The company's ...
